Analysts Conflicted on These Healthcare Names: Teleflex (TFX) and Blueprint Medicines (BPMC)
Blueprint Medicines | 10-Q: Quarterly report
Positive Outlook for Blueprint Medicines Driven by Strong Ayvakit Performance and Pipeline Progress
Earnings Call Summary | Blueprint Medicines(BPMC.US) Q1 2025 Earnings Conference
Blueprint Medicines Shares Are Trading Higher After the Company Reported Better-than-expected Q1 EPS Results and Raised Its FY25 Net Product Revenue Guidance.
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Blueprint Medicines (BPMC) and Ionis Pharmaceuticals (IONS)
Blueprint Medicines: Strong Financial Performance and Strategic Initiatives Justify Buy Rating
Blueprint Medicines | 8-K: Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
Blueprint Medicines Sees $700M-$720M in Global AYVAKIT Net Pdt Rev in 2025 >BPMC
Express News | Blueprint Medicines Reports First Quarter 2025 Results and Raises Ayvakit®/Ayvakyt® (Avapritinib) Full Year Revenue Guidance
Express News | Blueprint Medicines Q1 Operating Expenses USD 190.499 Million
Express News | Blueprint Medicines Q1 Net Income USD 496 Thousand Vs. IBES Estimate USD -35.6 Million
Press Release: Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT(R)/AYVAKYT(R) (Avapritinib) Full Year Revenue Guidance
Blueprint Medicines 1Q EPS 1c >BPMC
Earnings Scheduled For May 1, 2025
Here's the Major Earnings Before the Open Tomorrow
Blueprint Medicines Is Maintained at Buy by Needham
Needham Maintains Buy on Blueprint Medicines, Lowers Price Target to $130
Needham Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Cuts Target Price to $130
Goldman Sachs: The Q1 performance of U.S. pharmaceutical stocks is reassuring, and the Industry sentiment is slightly becoming more positive.
Goldman Sachs stated that amid cautious sentiment from investors towards the USA pharmaceutical sector before the Earnings Reports season, the performance of USA pharmaceutical companies that have reported results so far for the first quarter has not been worse than expected, and in some cases, it has even exceeded expectations.